FTSE MIB
30.403,90 +282,13 (+0,94%) Dow Jones
36.247,87 +130,49 (+0,36%) Nasdaq
14.403,97 +63,98 (+0,45%) Nikkei 225
32.307,86 -550,45 (-1,68%) Petrolio
71,26 +1,92 (+2,77%) Bitcoin EUR
41.122,96 +745,36 (+1,85%)
Editas Medicine, Inc. (EDIT)
Dopo ore:
| Chiusura precedente | 10,90 |
| Aperto | 10,81 |
| Denaro | 10,42 x 1000 |
| Lettera | 10,85 x 800 |
| Min-Max giorno | 10,42 - 11,18 |
| Intervallo di 52 settimane | 6,08 - 11,93 |
| Volume | |
| Media Volume | 1.750.955 |
| Capitalizzazione | 858,391M |
| Beta (5 anni mensile) | 1,96 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,69 |
| Prossima data utili | 20 feb 2024 - 26 feb 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 13,93 |
GlobeNewswireEditas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene editing medicine, for the treatment of severe sickle cell disease (SCD). “Sickle cell disease is a devastating disease that leads to anemia, pain crises, organ failure, and early death. Receiving RMAT
- GlobeNewswire
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Commercial and Strategy Officer, Caren Deardorf. In connection with Ms. Deardorf’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Ms. Deardorf as an inducement material to Ms. Deardorf entering into employment with Editas Medicine in accordan
GlobeNewswireEditas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
Caren Deardorf Editas Medicine, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer. CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine’s commercial organization, strategy, and execution to support a
